Biogen, Zydus Settle Patent Suit Over Copies of MS Drug Vumerity

Zydus Lifesciences Ltd. agreed to terms that would end a lawsuit brought by Biogen Inc. and Alkermes Plc over its proposed copy of the multiple sclerosis drug Vumerity, according to a court filing.

The agreement, which resolves all claims and defenses involving US Patent Nos. 8,669,281, 9,090,558, and 10,080,733, leaves the door open for the parties to renew their allegations, according to a stipulation and proposed order filed Wednesday in the US District Court for the District of Delaware.

The settlement came a day after Judge Gregory B. Williams postponed a bench trial’s start from July 28 ...